Drug repurposing for cancer therapy is currently a hot topic of research. Theoretically, in contrast to the known hurdles of developing new molecular entities, the approach of repurposing has several advantages. Mostly, it is said that it is faster, safer, easier, and cheaper. In the real world, however, there are only three repurposed drugs so far, that are listed in widely recognized cancer guidelines, but a large number of them are being studied. Among the many barriers to repurposing cancer drugs, economical-driven are the most important that difficult the clinical development of them. In this review, we provide an overview of the current status of drug repurposing for cancer therapy and the barriers that need to be overcome to realize the benefit of this approach. It means to have repositioned drugs for cancer therapy accepted as standard therapy for cancer indications at low cost.

用于癌症治疗的药物再利用是目前研究的热门话题。从理论上讲，与开发新分子实体的已知障碍相比，再利用的方法具有几个优点。大多数情况下，据说它更快、更安全、更容易、更便宜。然而，在现实世界中，迄今为止只有三种重新利用的药物被列入广泛认可的癌症指南，但其中大量正在研究中。在癌症药物再利用的众多障碍中，经济驱动是最重要的，也是它们临床开发的难点。在这篇综述中，我们概述了用于癌症治疗的药物再利用的现状以及实现这种方法的好处需要克服的障碍。